FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008188151> ?p ?o ?g. }

• W3008188151 abstract "Abstract Background Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify gene modules representing key biological pathways that relate to early AI therapy resistance. Methods Global gene expression was measured on pairs of core-cut biopsies taken at baseline and at surgery from 254 patients with ER-positive primary breast cancer randomised to receive 2-week presurgical AI ( n = 198) or no presurgical treatment (control n = 56) from the POETIC trial. Data from the AI group was adjusted to eliminate artefactual process-related changes identified in the control group. The response was assessed by changes in the proliferation marker, Ki67. Results High baseline ESR1 expression associated with better AI response in HER2+ tumours but not HER2− tumours. In HER2− tumours, baseline expression of 48 genes associated with poor antiproliferative response ( p < 0.005) including PERP and YWHAQ , the two most significant, and the transcription co-regulators ( SAP130 , HDAC4 , and NCOA7 ) which were among the top 16 most significant. Baseline gene signature scores measuring cell proliferation, growth factor signalling ( ERBB2-GS , RET/ GDNF-GS , and IGF-1-GS ), and immune activity ( STAT1-GS ) were significantly higher in poor AI responders. Two weeks of AI caused downregulation of genes involved in cell proliferation and ER signalling, as expected. Signature scores of E2F activation and TP53 dysfunction after 2-week AI were associated with poor AI response in both HER2− and HER2+ patients. Conclusions There is a high degree of heterogeneity in adaptive mechanisms after as little as 2-week AI therapy; however, all appear to converge on cell cycle regulation. Our data support the evaluation of whether an E2F signatures after short-term exposure to AI may identify those patients most likely to benefit from the early addition of CDK4/6 inhibitors. Trial registration ISRCTN, ISRCTN63882543 , registered on 18 December 2007." @default.
• W3008188151 created "2020-03-06" @default.
• W3008188151 creator A5001140222 @default.
• W3008188151 creator A5006665510 @default.
• W3008188151 creator A5019349196 @default.
• W3008188151 creator A5019381008 @default.
• W3008188151 creator A5020035024 @default.
• W3008188151 creator A5023115832 @default.
• W3008188151 creator A5023779153 @default.
• W3008188151 creator A5032209796 @default.
• W3008188151 creator A5035383163 @default.
• W3008188151 creator A5041130068 @default.
• W3008188151 creator A5043736497 @default.
• W3008188151 creator A5048117340 @default.
• W3008188151 creator A5058920702 @default.
• W3008188151 creator A5062099405 @default.
• W3008188151 creator A5068020071 @default.
• W3008188151 creator A5073889721 @default.
• W3008188151 creator A5089901983 @default.
• W3008188151 creator A5091210130 @default.
• W3008188151 date "2019-12-31" @default.
• W3008188151 modified "2023-10-18" @default.
• W3008188151 title "Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients" @default.
• W3008188151 cites W1977663202 @default.
• W3008188151 cites W2005156019 @default.
• W3008188151 cites W2006419043 @default.
• W3008188151 cites W2008359008 @default.
• W3008188151 cites W2011705265 @default.
• W3008188151 cites W2018445950 @default.
• W3008188151 cites W2033672070 @default.
• W3008188151 cites W2042198997 @default.
• W3008188151 cites W2062071674 @default.
• W3008188151 cites W2074420260 @default.
• W3008188151 cites W2081491080 @default.
• W3008188151 cites W2085934079 @default.
• W3008188151 cites W2091415346 @default.
• W3008188151 cites W2096283457 @default.
• W3008188151 cites W2097255042 @default.
• W3008188151 cites W2101979288 @default.
• W3008188151 cites W2113435829 @default.
• W3008188151 cites W2118949116 @default.
• W3008188151 cites W2123657823 @default.
• W3008188151 cites W2123945948 @default.
• W3008188151 cites W2130430382 @default.
• W3008188151 cites W2130594114 @default.
• W3008188151 cites W2138317169 @default.
• W3008188151 cites W2150134401 @default.
• W3008188151 cites W2159058669 @default.
• W3008188151 cites W2170674114 @default.
• W3008188151 cites W2214665719 @default.
• W3008188151 cites W2320186989 @default.
• W3008188151 cites W2414214572 @default.
• W3008188151 cites W2520255934 @default.
• W3008188151 cites W2550144082 @default.
• W3008188151 cites W2569724653 @default.
• W3008188151 cites W2574190322 @default.
• W3008188151 cites W2591893272 @default.
• W3008188151 cites W2592406193 @default.
• W3008188151 cites W2611921357 @default.
• W3008188151 cites W2743649404 @default.
• W3008188151 cites W2790920811 @default.
• W3008188151 cites W2794049848 @default.
• W3008188151 cites W2803733701 @default.
• W3008188151 cites W2887351902 @default.
• W3008188151 doi "https://doi.org/10.1186/s13058-019-1223-z" @default.
• W3008188151 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6938628" @default.
• W3008188151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31892336" @default.
• W3008188151 hasPublicationYear "2019" @default.
• W3008188151 type Work @default.
• W3008188151 sameAs 3008188151 @default.
• W3008188151 citedByCount "14" @default.
• W3008188151 countsByYear W30081881512020 @default.
• W3008188151 countsByYear W30081881512021 @default.
• W3008188151 countsByYear W30081881512022 @default.
• W3008188151 countsByYear W30081881512023 @default.
• W3008188151 crossrefType "journal-article" @default.
• W3008188151 hasAuthorship W3008188151A5001140222 @default.
• W3008188151 hasAuthorship W3008188151A5006665510 @default.
• W3008188151 hasAuthorship W3008188151A5019349196 @default.
• W3008188151 hasAuthorship W3008188151A5019381008 @default.
• W3008188151 hasAuthorship W3008188151A5020035024 @default.
• W3008188151 hasAuthorship W3008188151A5023115832 @default.
• W3008188151 hasAuthorship W3008188151A5023779153 @default.
• W3008188151 hasAuthorship W3008188151A5032209796 @default.
• W3008188151 hasAuthorship W3008188151A5035383163 @default.
• W3008188151 hasAuthorship W3008188151A5041130068 @default.
• W3008188151 hasAuthorship W3008188151A5043736497 @default.
• W3008188151 hasAuthorship W3008188151A5048117340 @default.
• W3008188151 hasAuthorship W3008188151A5058920702 @default.
• W3008188151 hasAuthorship W3008188151A5062099405 @default.
• W3008188151 hasAuthorship W3008188151A5068020071 @default.
• W3008188151 hasAuthorship W3008188151A5073889721 @default.
• W3008188151 hasAuthorship W3008188151A5089901983 @default.
• W3008188151 hasAuthorship W3008188151A5091210130 @default.
• W3008188151 hasBestOaLocation W30081881511 @default.
• W3008188151 hasConcept C104317684 @default.
• W3008188151 hasConcept C121608353 @default.
• W3008188151 hasConcept C126322002 @default.
• W3008188151 hasConcept C143998085 @default.
• W3008188151 hasConcept C150194340 @default.

• next